Tandem Diabetes Care, Inc. (NASDAQ:TNDM – Get Free Report) fell 7.4% during mid-day trading on Tuesday. The stock traded as low as $17.08 and last traded at $17.1150. 1,206,966 shares were traded during trading, a decline of 44% from the average daily volume of 2,171,074 shares. The stock had previously closed at $18.48.
Analysts Set New Price Targets
A number of brokerages recently issued reports on TNDM. UBS Group began coverage on Tandem Diabetes Care in a report on Tuesday, July 28th. They issued a “neutral” rating and a $18.00 price objective for the company. Truist Financial cut their target price on Tandem Diabetes Care from $31.00 to $28.00 and set a “buy” rating on the stock in a research note on Thursday, September 24th. Citigroup reduced their price target on Tandem Diabetes Care from $24.00 to $20.00 and set a “neutral” rating for the company in a research report on Wednesday, September 30th. Barclays increased their price target on Tandem Diabetes Care from $18.00 to $20.00 and gave the stock an “equal weight” rating in a research note on Friday, November 6th. Finally, Mizuho set a $20.00 price target on Tandem Diabetes Care in a report on Friday, November 6th. One equities research analyst has rated the stock with a Strong Buy rating, nine have issued a Buy rating, twelve have assigned a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of “Hold” and an average price target of $27.18.
Tandem Diabetes Care Stock Down 7.7%
The firm’s fifty day moving average price is $17.37 and its 200-day moving average price is $18.83. The company has a debt-to-equity ratio of 4.47, a current ratio of 3.20 and a quick ratio of 2.65. The firm has a market capitalization of $1.19 billion, a P/E ratio of -23.69 and a beta of 1.59.
Tandem Diabetes Care (NASDAQ:TNDM – Get Free Report) last posted its quarterly earnings data on Thursday, November 5th. The medical device company reported ($0.10) EPS for the quarter, beating analysts’ consensus estimates of ($0.25) by $0.15. The business had revenue of $283.69 million for the quarter, compared to analyst estimates of $265.85 million. Tandem Diabetes Care had a negative net margin of 4.58% and a negative return on equity of 35.61%. The business’s revenue for the quarter was up 13.8% on a year-over-year basis. During the same quarter last year, the business earned ($0.31) earnings per share. As a group, equities research analysts forecast that Tandem Diabetes Care, Inc. will post -0.61 earnings per share for the current year.
Insider Activity
In other news, Director Christopher J. Twomey sold 1,700 shares of Tandem Diabetes Care stock in a transaction on Tuesday, October 27th. The stock was sold at an average price of $19.15, for a total transaction of $32,555.00. Following the transaction, the director directly owned 24,434 shares in the company, valued at approximately $467,911.10. This trade represents a 6.50% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Company insiders own 2.10% of the company’s stock.
Institutional Trading of Tandem Diabetes Care
Institutional investors have recently modified their holdings of the company. First Light Asset Management LLC grew its holdings in Tandem Diabetes Care by 157.4% during the second quarter. First Light Asset Management LLC now owns 3,383,553 shares of the medical device company’s stock worth $51,058,000 after acquiring an additional 2,068,838 shares during the period. GW&K Investment Management LLC lifted its holdings in Tandem Diabetes Care by 13.0% in the 3rd quarter. GW&K Investment Management LLC now owns 2,903,529 shares of the medical device company’s stock valued at $47,357,000 after acquiring an additional 334,497 shares during the last quarter. Defilade Capital Management L.P. acquired a new stake in Tandem Diabetes Care in the 1st quarter valued at about $14,606,000. Quantinno Capital Management LP lifted its holdings in Tandem Diabetes Care by 123.5% in the 1st quarter. Quantinno Capital Management LP now owns 653,870 shares of the medical device company’s stock valued at $12,535,000 after acquiring an additional 361,361 shares during the last quarter. Finally, Toronto Dominion Bank bought a new position in shares of Tandem Diabetes Care during the 3rd quarter valued at about $8,308,000.
Tandem Diabetes Care Company Profile
Tandem Diabetes Care develops and commercializes technology for people who use insulin to manage diabetes. Its products include insulin pumps, infusion sets and related supplies, along with software for viewing and sharing diabetes-management data. The company’s offerings include the t:slim X2 insulin pump and the Tandem Mobi pump, as well as Control-IQ technology, which can automatically adjust insulin delivery based on continuous glucose monitor readings when used with compatible devices. Tandem also provides mobile apps and cloud-based tools to support users and healthcare providers.
Recommended Stories
- Five stocks we like better than Tandem Diabetes Care
- NVIDIA’s Turbulence Could Have Ripple Effects Across Quantum Computing
- Banking on AI: Can Upstart’s New Bank Plan Turn Its Stock Around?
- Amazon’s Black Friday Rush Could Kick Off a Holiday Season That Defines Its Year
- The Next Nuclear Opportunity May Be in Fuel, Not Reactors: 3 Stocks to Watch
Receive News & Ratings for Tandem Diabetes Care Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tandem Diabetes Care and related companies with MarketBeat.com's FREE daily email newsletter.
